智通财经APP获悉，中国生物制药(01177)早盘涨超3%，截至发稿，涨3.19%，报7.7港元，成交额1亿港元。
消息面上，7月30日，中国生物制药公布，该集团全资附属公司礼新医药科技(上海)有限公司(礼新医药)与默沙东就LM-299/MK-2010“PD-1/VEGF双抗”的对外授权合作进展顺利，该集团将于近期收到3亿美元的技术转移里程碑付款。
2025年7月29日，默沙东在二季度业绩会上披露，LM-299的技术转移已于7月完成，预计将于第三季度确认3亿美元的技术转移里程碑款项。此外，在电话会问答环节，默沙东回应分析师查询称，LM299项目正按计划如期推进。
据悉，2024年，礼新医药与默沙东就LM-299达成全球独家授权协议。根据协议条款，默沙东将获得LM299的全球开发、生产和商业化独家许可。礼新医药将获得5.88亿美元的首付款，以及最高27亿美元的里程碑付款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.